The last few decades have seen the remarkable development of spinal fixation devices. In current clinical use, devices are used to attach nearly every component of the spinal anatomy, including lamina, pedicles, spinous processes, facet joints, pars interarticuli and vertebral bodies. Unstable motion segments are often fused using constructs composed of plates, rods, wires and cages. Metals used include stainless steel, titanium and tantalum alloys. Ultimately, however, the success of any spinal fusion is dictated by biologic principles. Only a biologic environment conducive to bone formation and consolidation will allow successful osseous arthrodesis to occur.
Introduction
The last few decades have seen the remarkable development of spinal fixation devices. In current clinical use, devices are used to attach nearly every component of the spinal anatomy, including lamina, pedicles, spinous processes, facet joints, pars interarticuli and vertebral bodies. Unstable motion segments are often fused using constructs composed of plates, rods, wires and cages. Metals used include stainless steel, titanium and tantalum alloys. Ultimately, however, the success of any spinal fusion is dictated by biologic principles. Only a biologic environment conducive to bone formation and consolidation will allow successful osseous arthrodesis to occur.
Research efforts in the last decade have focused on morphogenetic proteins, opening exciting new avenues in spinal fusion surgery. Several osteoinductive growth factors, referred to as the bone morphogenetic proteins (BMP), have been shown to induce the transformation of undifferentiated mesenchymal cells into chondroblasts and osteoblasts, resulting in the formation of de novo bone [2, 18, 19, 22, 36, 42, 43, 47, 55, 72, 73] . Numerous preclinical animal studies have demonstrated the superiority of BMP implants over traditional autogenous bone grafts for a variety of orthopedic applications [17, 25, 29, 32, 37, 49, 66] . Considerable attention has been focused towards spinal applications for these innovative biologic tools, particularly for augmenting spinal fusion. Indeed, with the advances in molecular biology techniques, these proteins have been used in conjunction with gene therapy principles to deliver the protein at the desired fusion site in rats, leading to speculation as to "percutaneous" fusion in humans! The following sections thus summarize the key preclinical studies involving the BMPs and spinal fusion.
Abstract Preclinical investigations on the use of bone morphogenetic proteins (BMP) in the spine have yielded promising results. This has led to the preliminary introduction of these growth factors in controlled clinical trials. Initial data made available suggest that these differentiating factors will play a major role in the treatment of spinal disorders in the future. This article reviews key preclinical studies and their results that formed the basis for introduction into clinical trials. Non-primate and nonhuman primate models of spine fusion with BMP are reviewed objectively, and important issues regarding carrier, dose, and site of implantation are discussed. Finally, exciting new gene therapy research is dis-
Non-primate models

Demineralized bone matrix
The bone inductive activity of demineralized bone matrix (DBM) has been well established [15, 21, 24, 28, 34, 39, 68, 69, 71] . The primary osteoinductive component of DBM is a series of low-molecular-weight glycoproteins that includes the bone morphogenetic proteins (BMPs). The decalcification of cortical bone exposes these osteoinductive growth factors buried within the mineralized matrix, thereby enhancing the bone formation process [72] . The addition of autologous bone marrow and/or autograft to DBM provides an immediate source of osteogenic precursor cells at the implant site that may provide an additional biochemical contribution to osteogenesis [14, 69, 71] . DBM also appears to support new bone formation through osteoconductive mechanisms [45] . A number of well-controlled studies in a well-established and validated animal model of posterolateral spine fusion have demonstrated the suitability of various forms of DBM as a graft extender and, in some cases, as a graft enhancer and a graft substitute [45, 48] . Moreover, experimental studies have shown that osteoinductive bone protein growth factors combined with DBM produce biomechanically enhanced fusions as compared to autograft alone [4, 5, 6, 65] . DBM has a number of additional advantages that make it an attractive bone graft alternative. It is cost-effective and readily available from tissue banks. The demineralization process destroys the antigenic materials in bone, making DBM less immunogenic than mineralized allograft [30] .
DBM products were introduced clinically in 1991, and have since become the most widely used alternative graft product in spinal fusion surgery [57] . Case reports and analyses of several nonrandomized, retrospective clinical series suggest that DBM in combination with autologous marrow or bone demonstrates similar performance characteristics to autograft in posterolateral lumbar spine fusion [41, 61, 67, 70] .
Early experimental studies using DBM alone or in combination with autologous bone marrow (BM), autograft, or graft substitutes have reported spinal fusion rates comparable to autograft alone in rats [30] , rabbits [38, 39, 50, 51, 52, 53, 54], and dogs [27] . In addition, a number of studies have shown that DBM-autograft or BM composites demonstrate more rapid spinal fusion and appear to achieve radiographic and biomechanical stability earlier than autograft alone [27, 38, 39, 52]. Extrapolating these findings to humans is problematic, however, especially given that the majority of these studies have demonstrated efficacy of DBM in the less challenging anterior or posterior spine rather than the posterolateral spine and/or used animal models of spinal fusion that have not been characterized fully. Moreover, in many of these studies, all groups including the autograft group demonstrated 100% fusion rates, making it difficult to determine the added benefit of DBM over and above autograft [30, 50, 52] .
Boden and his colleagues conducted a series of investigations evaluating the efficacy of DBM in a well-characterized and validated animal model of posterolateral lumbar intertransverse process spinal fusion that closely resembles the surgical technique done in humans [4, 5, 6, 45, 48] . These authors have reliably demonstrated an outcome rate of fusion (nonunion rate of 35%) using autologous iliac crest graft that is similar to the rate of pseudoarthroses reported in humans. Moreover, the percentage of fusions that become solid does not change after 4-5 weeks. In these studies, fusion rates using DBM alone or in combinations with a variety of graft materials, including autograft, growth factors, and organic graft substitutes, have been compared to fusion rates using autograft iliac crest graft. Generally accepted measures of fusion based on manual palpation, histology, radiographs and/or biomechanical measures of stability were reported in all of these studies. In general, these studies have shown that certain formulations of DBM, when used alone, are insufficient to promote spinal fusion when placed in the more challenging posterolateral lumbar spinal fusion model in rabbits. When compared to autologous iliac crest bone graft, allogenic rabbit DBM alone resulted in significantly lower rates of fusion [4, 5] . The lower rate of fusion with allogenic DBM alone, as compared to autograft, was even more pronounced when DBM was evaluated in the highly challenging non-human primate model of lumbar posterolateral intertransverse process spinal fusion [5] . In primates, allogenic DBM alone resulted in minimal bone induction with no evidence of fusion at 12 weeks. Similar results were obtained using the gel form of DBM (Grafton) in a rabbit posterolateral lumbar arthrodesis model [48] . In this study, gel-DBM did not increase the fusion rate when added to a standard amount of iliac crest autograft. The addition of gel-DBM to less than the standard amount of autograft did, however, result in fusion rates (70% and 66%) that were comparable to autograft alone (73%). Gel-DBM was most effective in producing fusion rates that mirrored those of autograft when used with autograft in a 3:1 ratio. These authors concluded that, while gel-DBM did not meet criteria as a graft substitute or a graft enhancer (i.e., when added to the usual or a decreased amount of autogenous bone yields a higher rate of successful fusion than autograft alone), gel-DBM did demonstrate properties of a viable graft extender (i.e., when added to autologous bone yields a rate of successful fusion equal to that of autologous bone graft alone).
Other formulations of DBM have shown greater success at inducing spinal fusion when used as stand-alone agents. In a recent study by Martin et al., two new formulations of Grafton DBM (flex-DBM and putty-DBM) were found to be effective as both a graft extender and graft enhancer in the challenging rabbit model of posterolateral spine fusion, as well as demonstrating the capacity to serve as a potential osteoconductive graft substitute [45] . Historical controls allowed comparisons to gel-DBM. In contrast to gel-DBM, which is particle based, the new formulations of Grafton are fiber-containing, and demonstrate improved handling characteristics compared with the gel. Flex-DBM is a flexible sheet of Grafton fibers, whereas putty-DBM is made in a malleable consistency. Previous studies, conducted by Edwards and co-workers in an athymic rat heterotopic implant model, demonstrated that the gel-DGM, flex-DBM and putty-DBM had equivalent osteoinductive capacities [23] . Both the flexand putty-DBM showed significantly superior fusion rates to gel-DBM and to autograft alone (100%, 83%, 58% and 73%, respectively). When combined with a less than standard amount of autograft (1.5 ml), both composites had significantly superior fusion rates (100%) to autograft alone (33%) and to gel-DBM combined with autograft (70%). Edwards concluded that these two formulations of DBM demonstrated a potential as both a graft extender and graft enhancer, since each performed better than autograft alone when used as stand-alone agents or when combined with autograft. They further postulated that the new formulations of DBM enhance fusion over and above that of gel-DBM combined with autograft, because these fibercontaining formulations may be more osteoconductive than gel-DBM. When flex-, putty-and gel-DBM were devitalized by guanidine extraction, thereby removing the osteoinductive factors, and then compared to devitalized gel-DBM in terms of bone formation, the devitalized flexand putty-DBM formulations showed significantly more new bone formation than devitalized gel-DBM, suggesting an enhanced ability to serve as an osteoconductive graft substitute. The flex formulation used in these studies was fluffier than the original human flex, and this form has now been produced for human use and is called Grafton Matrix.
A number of bioceramics such as sea coral and hydroxyapatite (HA) have been used in comparison to and in combination with DBM in animal models of spine fusion [5, 52, 54] . Ragni and his colleagues evaluated the efficacy of DBM with porous hydroxyapatite (HA) in an anterior lumbar interbody spinal fusion model in rabbits [52, 54] . They reported that HA blocks alone or in combination with DBM had similar radiographic fusion scores to autograft alone or autograft with DBM and BM at 2 months. By 6 months, all groups had stable fusions on dynamic radiographs, with the exception of the group that received no implant. The earliest signs of fusion on dynamic radiographs were achieved in the group implanted with the HA-DBM composite, although, according to the authors, statistical comparisons could not be calculated, because of the insufficient number of observations in the autograft alone group and the group that received no implant [52] . Using a well-characterized and validated rabbit model of posterolateral lumbar spinal fusion, Boden and his co-workers found significantly lower rates of fusion with DBM alone (17%) and biocoral alone (0%) at 5 weeks when compared to autograft alone (62%) [5] . In this study, the addition of bovine-derived bone growth factor extract (bone protein, BP) to DBM, to autograft, and to natural coral resulted in 100% fusions in each of these groups by 5 weeks. Furthermore, the addition of BP to either DBM or biocoral significantly increased the biomechanical strength and stiffness of fusion when compared to BP combined with autograft.
The role of osteoinductive growth factors as an adjunct to enhance spinal fusion is an area of intense experimental investigation. First isolated by Urist from bone in a partially purified form, these growth factors appear to hold the greatest promise for graft alternatives in the challenging environment of the posterolateral spine [69, 71] . A number of investigators have since investigated DBM in conjunction with a variety of osteoinductive growth factors, including bovine-derived osteoinductive protein extract (BP) [4, 5, 6, 65] and recombinant human bone morphogenetic protein 2 (rhBMP-2) [33] . In general, these studies have shown that successful spinal fusion can be achieved using osteoinductive growth factors combined with different carriers, including DBM. Boden et al. demonstrated successful fusion in both the rabbit and primate model of posterolateral spine fusion using BP with a DBM carrier [4, 5, 6] . In the rabbit model, DBM combined with BP demonstrated significantly higher fusion rates as compared to autologous iliac crest graft or to DBM alone. Moreover, the fusion masses in the BP-DBM composite group were significantly stronger and stiffer on biomechanical testing compared to the autograft group with or without the bone protein, perhaps reflecting the impact of the homogeneity of the bone protein-carrier implant on bone remodeling. The more homogeneous fusion mass associated with either DBM or biocoral (i.e., masses consisting of uniform small particles) may be more amenable to bone remodeling and reach biomechanical maturity more quickly than the less homogeneous fusion mass found with autograft (i.e, masses composed of variably sized larger bone pieces) [5] . These authors also noted a dose-dependent response to BP, with 100% fusion at the higher concentration (300 µg BP) and 50% fusion at the lower concentration (100 µg BP), indicating that a threshold must be overcome before bone formation is induced [5] . An eight-fold increase in BP concentration (µg bone protein/g DBM carrier) was required to induce adequate bone formation in the rhesus monkey spine.
In contrast to results indicating improved biomechanical properties when an osteoinductive growth factor is combined with a DBM carrier [4, 5, 6], two studies from different laboratories have reported significantly decreased biomechanical characteristics in the growth factor-DBM carrier groups [33, 65] . Using a unilateral posterior lumbar decompression and contralateral spine fusion model in dogs, Helm and his colleagues [33] compared five groups: autograft alone, autograft with DBM, autograft with Type I collagen gel, autograft with DBM and collagen gel, and autograft with rhBMP-2. At 3 months, all groups without DBM demonstrated histological and radiographic evidence of fusion, with the rhBMP-2+ autograft group showing the largest fusion mass. Furthermore, all groups with DBM (including the autograft with DBM group) demonstrated markedly lower rates of fusion and decreased biomechanical strength and stiffness compared to groups that did not contain DBM. These disparate findings may be partially explained by differences in the methods used to process the DBM [3]. These authors utilized a demineralization process [13] that differs from the process as originally promulgated by Urist [71] and from the one utilized in the series of studies conducted by Boden and his colleagues [4, 5, 6, 65] . Moreover, the animal model of spinal fusion utilized by these authors (i.e, unilateral decompression and contralateral intralaminar fusion) is relatively unique, making extrapolation of their findings to the more common posterolateral intertransverse process model of spinal arthrodesis difficult.
Silcox et al. found mixed results in a novel experiment designed to evaluate the efficacy of the bovine-derived bone growth factor (BP) in a nicotine rabbit spinal fusion model [65] . This model involves the continuous infusion of nicotine via a subcutaneous implanted miniosmotic nicotine pump, and has been shown to yield a nonunion rate of 100% as compared to the nonunion rate in the nonnicotine model of 35% using autologous iliac crest graft [64] . Silcox et al. reported 100% fusion at 5 and 10 weeks in the BP with autograft group as compared to 64% fusion in the BP with DBM group and 0% fusion with autograft alone. In contrast to previous studies [4, 5, 6], the biomechanical properties of the BP-DBM composite group were significantly lower than the BP-autograft group, with the authors noting a marked degree of graft resorption and an absence of fusion mass formation in 20% (2/10) of the animals in the BP-DBM group.
In summary, a number of well-controlled studies in a validated model of posterolateral spinal fusion have demonstrated that certain formulations of DBM can function as viable bone graft alternatives. The combination of osteoinductive growth factors with suitable osteoinductive and osteoconductive carriers, such as DBM, appears to be an especially potent promoter of spinal fusion in both lower-and higher-order animal models.
Bone morphogenetic proteins
Lovell et al. determined the efficacy of partially purified bovine BMP (bBMP) in a four-level alternating thoracic fusion model (T6-T13) in canines [40] . Four variations were used, including local autograft with bBMP, local autograft with a polylactic acid carrier for bBMP, local autograft alone and decortication alone. Fusions were assessed radiographically and histologically. The bBMP and autograft groups had the highest fusion rate (71%) compared with the other conditions (29%, 14% and 0% respectively). The bBMP/autograft combination produced a larger fusion mass with a more rapid fusion rate than that of autogenous spinous process graft alone.
Through genetically modified cell lines, recombinant bone morphogenetic protein has been produced as singular molecular species in unlimited quantities. Recombinant human BMP (rhBMP) does not cause a host-versusgraft immune response, and is free of infectious agents and contaminants.
Recombinant human osteogenic protein (rhBMP-7, rhOP-1) was evaluated as a bone graft substitute for spinal fusion in a canine posterior lumbar fusion model by Cook et al. [18] . Within 12 weeks, solid fusions were obtained with 2.0 mg of the growth factor, compared with 26 weeks in the autogenous iliac bone graft group. Magin evaluated rhBMP-7 in a sheep lumbar interbody fusion model [44] . An L4-L5 fusion was performed in three groups of ten sheep each. The first group received autograft, the second received deproteinized bovine hydroxylapatite, and the third group received rhBMP-7 on a collagen carrier. Radiographs demonstrated solid fusions in eight of ten sheep in the rhBMP-7 group at 4 months; at 6 months, equal volumes of bone were seen in both the autograft group and the rhBMP-7 group. According to histology and histomorphometry 6 months postoperatively, the rhBMP-7 group showed the highest bone density in the area of the fusion.
Schimandle et al. used rhBMP-2 in a rabbit model of lumbar intertransverse process arthrodesis and compared it with fusions obtained with autogenous bone graft [62] . Different doses and different carriers for rhBMP-2 were used in this study. All rabbits in the experimental group achieved solid spinal fusion as assessed by manual palpation and radiographs, whereas only 42% of the autograft control group achieved fusion. Rabbits implanted with high-dose rhBMP-2 had more mature fusions with greater trabecular bone formation than those rabbits implanted with low-dose rhBMP-2. Sheehan et al. examined the spinal fusion enhancement potential of rhBMP-2 in a unilateral posterolateral canine spine fusion model [63] . Their four experimental groups consisted of the following: autogenous bone graft alone, autogenous bone graft plus collagen, no implant, and autogenous bone, collagen and rhBMP-2. Radiographic assessment, three-dimensional computed tomographic volumetric analysis and biomechanical testing were performed. The average fusion volume and flexion and extension biomechanical properties were significantly greater in the rhBMP-2/autograft/collagen group as compared to the other groups. The results of this study indicated that the most advantageous spinal fusion implant matrix consisted of rhBMP-2, autogenous bone graft and collagen. Sandhu et al. evaluated rhBMP-2 using a canine posterior lumbar intertransverse process fusion model, and found that at 3 months, solid single-level fusion was achieved, with similar volumes of de novo bone across a wide range of doses [59] . Fusion was not achieved in animals with autogenous iliac crest graft alone. The same group then studied whether decortication was essential for successful fusion in the presence of rhBMP-2. Traditionally, achieving successful spinal fusion relies on the exposure of bone marrow through decortication of the posterior elements, hence releasing osteoinductive proteins. The authors hypothesized that the use of an implanted osteoinductive protein (rhBMP-2) would obviate the need for exposure and release of the growth factors. A canine model was utilized with L4-L5 transverse process fusions performed with and without decortication and with varying doses of rhBMP-2. Their results indicated no statistical differences in clinical and radiographic fusion rates between decorticated and undecorticated groups.
Boden et al. examined the efficacy of minimally invasive, video-assisted lateral intertransverse process arthrodeses using rhBMP-2 delivered in a collagen sponge carrier in two different animal models [8] . There were three arms to this study. In the first arm, they used a rabbit model to develop the minimally invasive technique, which then was modified for a primate (rhesus monkey) model. The second arm consisted of three parts:
1. A group of rabbits that underwent standard open-muscle splitting approach using rhBMP-2 and collagen 2. A video-assisted control group that underwent videoassisted lateral intertransverse arthrodesis with collagen implant only, and 3. A video-assisted BMP group that underwent video-assisted lateral intertransverse arthrodesis with rhBMP-2 and collagen as graft material
The third and final arm consisted of rhesus monkeys that underwent video-assisted lateral intertransverse arthrodesis with rhBMP-2 and collagen after laminectomy of L4-L5. All experimental animals implanted with rhBMP-2 went on to solid fusion. The results of this study thus indicated that video-assisted intertransverse process arthrodesis was a feasible and effective method of lumbar spine fusion in the rabbit and rhesus monkey. Anterior spinal column fusion using rhBMP-2 has also been investigated. Sandhu et al. implanted cylindrical and threaded titanium intervertebral body fusion devices containing rhBMP-2 without autograft in a sheep anterior lumbar interbody fusion model [58] . They demonstrated consistent and rapid interbody intervertebral osseous fusion through the fixation device in 100% (six of six) cases. On the other hand, only 33% (two of six) control animals implanted with the fusion cage containing autograft alone achieved solid fusion. In the same model, Sandhu et al. added rhBMP-2 to porous tantalum cylindrical cages and showed that significantly greater bone ingrowth occurred in the porous macrostructure compared with cages that had not been combined with the rhBMP-2
in a sheep model with a threaded cylindrical fusion cage containing either rhBMP-7 or autogenous bone graft derived from the iliac crest [20] . They found fusion rates for the two study groups to be comparable (63%).
Non-human primate models
There is evidence to suggest that the concentration of cells receptive to the growth factors decreases as the evolutionary complexity of the animal increases. Hence, osteoinductive agents may demonstrate desirable effects in a lower species but not in a higher species. As a result, nonhuman primate models have been investigated in an attempt to mimic the physiologic processes in humans.
Cheung et al. assessed the efficacy of rhBMP-7 used with autologous corticocancellous bone to accelerate intertransverse lumbar fusion in a primate model [16] . Twelve monkeys were divided into two groups; one group receiving autograft soaked in a solution of rhBMP-7 and the second receiving autograft soaked in the carrier solution alone. Fusion was assessed by monthly radiographs and after sacrifice at 5 months, by gross inspection, histological examination and mechanical testing. There was no statistical difference in fusion rate histologically or biomechanically between the two groups (16% in the autograft group vs 66% in the rhBMP-7 group). The authors concluded that the potent osteoinductive characteristics of rhBMP-7 in lower animals did not translate to primates.
Boden et al. examined a purified bovine osteoinductive bone protein extract in the posterior lumbar spines of adult male rhesus monkeys [7] . Animals that were implanted with 3000 µg or more of the growth factor achieved single-level intertransverse process fusion. Spines implanted with lesser doses of the osteoinductive factor did not proceed to fusion. At the same institution, using the same intertransverse process fusion models, Boden et al. found rhBMP-2 to result in a 100% fusion rate with all three different doses tested [11] . The carrier alone and autograft treated control animals did not result in any fusions (0%). At the same institution, Boden et al. also investigated laparoscopic anterior spinal arthrodesis with rhBMP-2 in a primate model [9] . The rhBMP-2 was carried on a collagen sponge in a threaded titanium interbody cage for anterior L7-S1 fusion. Solid fusion was achieved in all five of the animals that had been implanted with the growth factor, as demonstrated histologically. Successful fusion did not occur in either of the two animals that were implanted with the collagen sponge alone. Hecht et al. studied the efficacy of rhBMP-2 in a rhesus macaque monkey anterior interbody fusion model, using cylindrical freezedried allograft bone dowels [31] . These dowels were filled with either rhBMP-2-soaked collagen sponges or autogenous bone graft from the iliac crest. Radiographic S126 signs of fusion were demonstrated as early as 8 weeks after implantation, with complete fusion, as evidenced by radiology and histology, by 6 months. There was also evidence by this time of resorption of the allograft and replacement of de novo bone. These changes were not found in the control group, consisting of cortical dowels filled with autogenous bone graft.
Delivery vehicles for BMP
Although the osteoinductive capacity of recombinant BMP has been demonstrated in several models, the optimal method for delivering the protein to inducible cells has not yet been established. BMPs are soluble molecules that, when implanted alone, diffuse too rapidly to allow osteoinduction to occur. In general, a suitable carrier must consist of the following properties: it should provide controlled release of the protein, adequate exposure to inducible cells, be biocompatible with host tissue and have an architecture conducive to the rapid ingrowth of newly formed bone. For posterolateral spine fusions, a load-bearing delivery vehicle is not required, particularly when load bearing spinal fixation devices are also used. The delivery vehicles for this indication are responsible for primarily exposing the osteoinductive protein to induce pluripotent stem cells residing in local mesenchymal tissue and maintaining space for subsequent bone formation of the fusion mass. In contrast, load-bearing carriers are required for certain indications, such as anterior interbody fusion.
Fischgrund et al. evaluated the use of rhBMP-2 with various types of carrier media and the effect of rhBMP-2 with autogenous bone graft in a canine spine fusion model [26] . Bilateral intertransverse spine fusions were performed in six canines at L1-L2, L3-L4 and L5-L6 using autogenous iliac crest bone graft at each level. Hence, the 18 segmental fusion sites were randomly assigned one of six fusion methods:
1. Autogenous bone graft alone 2. Autogenous bone graft+rhBMP-2 3. Autogenous bone graft+collagen "sandwich"+rhBMP-2 4. Autogenous bone graft+collagen morsels+rhBMP-2 5. Autogenous bone graft+polylactic glycolic acid (PLGA) sponge "sandwich"+rhBMP-2, and 6. Autogenous bone graft+open-pore polylactic acid morsels+rhBMP-2
Their results indicated that the addition of rhBMP-2 significantly increased bone graft volume as assessed by computerized tomography (CT), but no significant difference was noted in carrier media for rhBMP-2. However, the use of PLGA as a carrier was associated with a higher rate of fusion mass bone void formation. Martin et al. compared different combinations of rhBMP-2 dosages and carriers in an adult male primate (rhesus) model [46] . The main findings of this study were that rhBMP-2 could induce bone in the non-human primate and that, when protected from the "squeezing" influence of soft-tissues, collagen carriers allowed more bone induction at lower doses of rhBMP-2. Similarly, Boden et al. used the same model to evaluate various doses of rhBMP-2 in a ceramic (hydroxyapatite-tricalcium phosphate, HA-TCP) carrier as a complete bone graft substitute [11] . The theory behind using a ceramic carrier was that, although resorbable collagen sponges have shown promise in rabbit and canine models of spine fusion, it was too compressible for the paraspinal muscles in rhesus monkeys, as demonstrated by Martin and co-workers (see above). Twenty-one adult rhesus monkeys underwent laminectomies at L4-L5, followed by bilateral intertransverse process arthrodesis via a classic midline incision or minimally invasive video-assisted posterolateral approach. On each side, a 5-cm 3 implant of either autogenous bone graft or 60:40 HA-TCP was placed. The ceramic carrier was loaded with a varying range of doses of rhBMP-2. Fusion was not achieved in the autogenous bone graft alone group, whilst all the experimental animals in the HA:TCP group, irrespective of the dose of rhBMP-2 loaded, achieved solid fusion. These results prove that HA:TCP can be a suitable carrier for rhBMP-2 in a primate posterolateral spine fusion model.
Considerable work in the field of cytokine delivery is still needed. Development and refinement of an appropriate carrier that releases growth factors in a dose-dependent, predictable and continuous fashion is needed. The development of such a carrier may be the most crucial step prior to widespread clinical use.
Gene therapy models and BMP
Recently, there has been interest in exploring the efficacy of regional gene therapy for spine fusions [35] . Preliminary results of this technique in preclinical animal work is exciting; however, there are several issues that remain to be settled before one can advocate the widespread use of gene therapy for spinal fusion. In theory, the effect of transduced cells continuously producing growth factors at the desired site until a solid fusion results is attractive; however, dosage and carrier issues still remain to be settled.
Riew et al. attempted to prolong the bone-inducing effect of bone morphogenetic protein-2 using an adenoviral vector carrying the human BMP-2 gene to transduce marrow-derived mesenchymal stem cells in New Zealand White rabbits [56] . In their model, they isolated and expanded bone marrow mesenchymal cells (MSC) from the resected ribs. Immunocytochemistry was used to show that approximately 80% of MSCs could be genetically modified to over-express BMP-2 protein by treatment with an adenoviral vector encoding human BMP-2 (Adv-BMP-2). A similar efficiency of gene transfer was demonstrated with the control vector encoding a marker gene E.coli ß-galactosidase (Adv-ß-gal).
Four weeks after rib harvest, the rabbits underwent spinal fusion at L5-L6. Genetically modified mesenchymal stem cells loaded onto collagen sponges were placed between the transverse processes of L5 and L6, with Adv-BMP-2 transduced MSCs placed on the left side and the Adv-ß-gal on the right.
After the 2nd postoperative week, all rabbits were examined radiographically weekly. Of the five study rabbits, one showed radiographic evidence of new bone formation on the side implanted with Adv-BMP-2, 5 weeks after surgery. No new bone was noted on the control Adv-ß-gal side. No new bone formation was observed on either side in the other four study rabbits. Rabbits were sacrificed 7 weeks after the operation, and histologic examination of the rabbit with new bone revealed mature bone with a trabecular structure. Histology was unremarkable in the control side. The authors thus concluded that it was possible to transduce mesenchymal stem cells with hBMP-2 gene so the transformed cells could produce BMP-2 in vivo that would exert an osteoinductive effect. These initial results, however, warranted further work on the longevity and efficiency of the gene transfer.
In a related study, Alden et al. investigated the effect of percutaneous spinal fusion using BMP-2 with adenovirusmediated gene transfer techniques in an athymic (immunocompromised) rat model [1] . The 12 rats were divided into three groups of four rats each. All groups underwent paraspinal percutaneous injection with 7.5 µl of virus via a Hamilton microsyringe inserted through a 19-G guide needle placed at the junction of the spinous process and the lamina on each side. The groups were as follows:
1. Adv-BMP-2 bilaterally 2. Adv-BMP-2 on the right, Adv-ß-gal on the left, and 3. Adv-ß-gal bilaterally CT scans of the lumbosacral junction were obtained at weeks 3, 5, 8, and 12. Twelve weeks following injection, the rats were sacrificed and studied histologically.
Examination of CT scans at each time point revealed new bone formation adjacent to the spinous processes and laminae at each of the Adv-BMP-2 injected sites, but no changes were observed at the Adv-ß-gal control sites. Histology of the Adv-BMP-2 sites 12 weeks following injection revealed extensive endochondral bone formation within the paraspinal musculature, with well-developed vascular channels and areas of cartilage as well as trabecular bone and mature marrow elements. New bone formed was in direct continuity with the adjacent laminae, inferior facets and the spinous process. No new bone formation was detected in the Adv-ß-gal control animals. The authors concluded that in vivo endochondral bone formation was possible using direct adenoviral construct injection into the paraspinal musculature, and suggested that this approach could potentially be used for spine fusion in the future.
Wang et al. transfected marrow cells with an adenoviral vector to produce BMP-2 in a rat intertransverse spinal fusion model [74] . Bone marrow was harvested from syngeneic Lewis rats and expanded in tissue culture. These cells were genetically modified using Adv-BMP-2. The transfected cells were then soaked onto a guanidiun extracted, deactivated demineralized bone matrix carrier and implanted into the rat spine between the transverse processes of L4 and L5. Fifty-six rats were divided into a total of seven groups:
1. Adenovirus-modified BMP-2 producing marrow cells 2. Recombinant BMP-2 protein 3. Demineralized bone matrix alone 4. Cells transfected with a control gene 5. Decortication of the transverse processes alone 6. Autogenous iliac crest bone graft, and 7. Normal (not genetically modified) bone marrow cells with demineralized bone matrix Outcome assessment to determine fusion was performed by inspection, plain radiographs, manual palpation and histologic evaluation. At 4 weeks, all rats that had been implanted with adenovirus-modified BMP-2 producing marrow cells demonstrated 100% fusion. All rats (100%) that had been implanted with recombinant BMP-2 alone also had complete arthrodesis by 4 weeks. All other groups did not demonstrate fusion at 8 weeks. The data of this study confirmed that regional gene therapy utilizing BMP-2 producing bone marrow cells produced by adenoviral gene transfer could be successfully used in a rat model of intertransverse spine fusion, opening further avenues for its potential use in humans.
Conclusions and future directions
The studies reviewed above represent a few examples of the exemplary work being conducted in the arena of bone morphogenetic proteins and spinal fusion research. The initial findings of clinical trials using rhBMP-2 have been published, and the spectacular results indicate that the widespread use of BMPs in spine fusion may become a reality fairly soon [12] . However, several questions remain to be answered. The exact dose required for each specific fusion site (posterolateral vs anterior interbody) remains to be comprehensively determined in humans. Furthermore, optimal site-specific carriers are still in the developmental stage. The use of collagen-soaked cortical bone dowels for anterior interbody fusions seem promising in this regard. The overall cost of the device to be implanted will also factor into the use of BMPs for spinal fusion in the future.
One interesting development recently has been the isolation and delivery of an upstream transcription factor that upregulates the expression of multiple BMPs and other S128 S129 factors at the fusion site for sustained protein release [10] . This has been shown to have a powerful recruitment effect on other growth factors and cells to form bone in a rat lumbar spine fusion model. Development of this avenue is underway, and the future controversies on the use of BMPs will include the question of whether it is safer, more costeffective and more efficacious to use a single large dose at the fusion bed or to use gene therapy mediated techniques for fusion. Relevant factors will include number of levels requiring fusion, metabolic health of the patient, immunological status, osteoporosis and age-mediated decrease in responding pluripotent cells.
Before one can make any definitive arguments, not only is further basic research required to elaborate the biological functioning of each of the BMPs, but further carefully designed, prospective, randomized clinical trials are essential to validate their potential use in the spine. 
